Your event should be here ! To publish, manage, promote... To learn or to be formed ... Online registrations

Site language : English - Français
Ref : 33042
Event :12th Annual World Bispecific Summit

Dates :Wednesday September 29th, 2021 - Friday October 01st, 2021

Location :Online (Internet, Videoconferencing, ...)

Type :Conference & Seminar - International audience

Accreditation :--


Further information

The 12th World Bispecific Summit has established itself as the key industry-led networking forum to gain clear insights into the latest discovery, translational and manufacturing advancements, and how to address associated development challenges encountered within this therapeutic modality.

If your research teams are looking to tackle major challenges in bispecific drug functionality, including tumor-specific antigen targeting, binding affinity; or multi-specific antibody formats, this elite conference presents an insight that can influence the design and development of your product. Whether it is a CD3-engaging T-cell re-directing BsAbs targeting checkpoint inhibitors or a tumor-associated antigen, this is the key industry meeting you should be attending.

Alongside clinical development questions, this definitive forum will provide direction on the developability of BsAbs platforms, with dedicated sessions on product expression, purification, product stability, and scale-up of the manufacturing process.

Time: 10:00 am - 5:00 pm


Conference + Focus Day - Industry Pricing: USD 2798.00,
Conference Only - Industry Pricing: USD 2199.00,
Conference + Focus Day - Academic and Non-Profit Pricing: USD 2398.00,
Conference Only - Academic and Non-Profit Pricing: USD 1899.00





Speakers: Nicolas Poirier, Chief Scientific Officer, OSE Immunotherapeutics, Nimish Gera, Head of Biologics, Mythic Therapeutics, Markus Zettl, Director Immunooncology, Pieris Pharmaceuticals, Ivan Mascanfroni, Director Immunology Discovery, Pandion Therapeutics, Yanjing Li, Senior Scientist - Cell Line Development / CMC Lead, Boan Boston, Carston Wegner, Professor of Medicinal Chemistry, University of Minnesota, Julie Bailis, Director of Research, Amgen, Suzanne Schubbert, Group leader Cell Biology, Xencor, Laura Codarri Deak Principal Scientist Cancer Immunotherapy Roche, Brad Sumrow, Director Clinical Research, MacroGenics, Chad May, Senior Vice President, R&D, Maverick Therapeutics, Katherine Harris, Vice President, Discovery, TeneoBio, Matthew Bernett, Director of Protein Engineering, Xencor, Stanislas Blein, Chief Scientific Officer, Ichnos Sciences, Eric Vivier, Chief Scientific Officer, Innate Pharma, Matthew Chun, Senior Scientist, Amgen, Anthony Stein, Director, Leukemia Program Codirector, Gehr Family Center for Leukemia Research, City of Hope, Koustubh Ranade, Head of Translational Medicine, Immunocore, Ryan Potts, Executive Director and Head of IPP, Amgen, Eva Hansbauer, Associate Director of Protein Analytics, Pieris Pharmaceuticals, Adam Chervin, Principal Research Scientist II, Abbvie, Oren Bogin, Chief Executive Officer, Explore Bio, Angus Sinclair, VP Immunooncology Research, IGM Biosciences, Wim van Schooten, Chief Scientific Officer, TeneoBio, Li Zhou, VP Cell Therapy and Antibody Research, Boan Boston, Xiaotian Zhong, Senior Principal Scientist and Laboratory Head, Pfizer, Victoria Smith, Chief Scientific Officer, Amphivena Therapeutics, Sara Mangsbo, Associate senior lecturer, and Co-founder, Uppsala University, Strike pharma AB, Sean Durning, Senior Scientist I, Abbvie, Paolo Meoni, Project Head, Sanofi, Genevive Hernandez, Director of Clinical Biomarkers, IGM Biosciences, Paul Moore, VP Immunology and Cell Biology, MacroGenics, Mark Chiu, President Tavotek, Therapeutics, Marta Germani, Research Analyst, Beacon Targeted Therapies, Teemu Junttila, Principal Scientist - Translational Oncology, Genentech, Martin Schroeder, Chief Technology Officer, GT Biopharma, Mohamed Elmeliegy, Associate Director - Clinical Pharmacology, Pfizer, Walter Ferlin, Chief Scientific Officer, Light Chain Bioscience – Novimmune SA, Bryan Lemon, Director Protein Sciences, Harpoon Therapeutics, Regis Cebe, Principal Scientist II, Novartis Biologic Center, NIBR Novartis Pharma AG, Pieter Fokko van Loo, Senior Director Oncology Immunology, Merus, Yves Poitevin, Head of Bioprossessing, Light Chain Bioscience – Novimmune SA, Jane Gross, Chief Scientific Officer, Aptevo Therapeutics, Nelly Kirklin, VP Immunology, Compass Therapeutics, Erin Meermeier, Senior Research Fellow, Mayo Clinic, Umesh Muchhal, Senior Director Protein Sciences, Xencor, Tatiana Novobrantseva, Chief Scientific Officer, Verseau Therapeutics, Samuel Pine, Head of Bioanalysis and Immunogenicity, Ablynx, Amy Que, Chief Technology Officer, Harbour Biomed, Eugene Zhukovsky, Chief Technology Officer, Go Therapeutics, Darshana Jani Director, Global Bioanalysis, Agenus inc

Further information

To access the information you need to be connected. Creating an account is easy and free!

Log to your account
Register on Doctorama


12th Annual World Bispecific Summit Medicine - Pharmacy - Oncology
tumor, bispecific, bispecifictherapeutics, cytokine, solidtumor
1000 -- --

Recommend this event